DNA methylation markers for early detection of women's cancer: promise and challenges

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F14%3A10284747" target="_blank" >RIV/00216208:11110/14:10284747 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064165:_____/14:10284747

Výsledek na webu

<a href="http://dx.doi.org/10.2217/EPI.14.20" target="_blank" >http://dx.doi.org/10.2217/EPI.14.20</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.2217/EPI.14.20" target="_blank" >10.2217/EPI.14.20</a>

Jazyk výsledku

angličtina

Název v původním jazyce

DNA methylation markers for early detection of women's cancer: promise and challenges

Popis výsledku v původním jazyce

Breast, ovarian and endometrial cancers cause significant morbidity and mortality. Despite the presence of existing screening, diagnostic and treatment modalities, they continue to pose considerable unsolved challenges. Overdiagnosis is a growing problemin breast cancer screening and neither screening nor early diagnosis of ovarian or endometrial cancer is currently possible. Moreover, treatment of the diversity of these cancers presenting in the clinic is not sufficiently personalized at present. Recent technological advances, including reduced representation bisulfite sequencing, methylation arrays, digital PCR, next-generation sequencing and advanced statistical data analysis, enable the analysis of methylation patterns in cell-free tumor DNA in serum/plasma. Ongoing work is bringing these methods together for the analysis of samples from large clinical trials, which have been collected well in advance of cancer diagnosis. These efforts pave the way for the development of a noninva

Název v anglickém jazyce

DNA methylation markers for early detection of women's cancer: promise and challenges

Popis výsledku anglicky

Breast, ovarian and endometrial cancers cause significant morbidity and mortality. Despite the presence of existing screening, diagnostic and treatment modalities, they continue to pose considerable unsolved challenges. Overdiagnosis is a growing problemin breast cancer screening and neither screening nor early diagnosis of ovarian or endometrial cancer is currently possible. Moreover, treatment of the diversity of these cancers presenting in the clinic is not sufficiently personalized at present. Recent technological advances, including reduced representation bisulfite sequencing, methylation arrays, digital PCR, next-generation sequencing and advanced statistical data analysis, enable the analysis of methylation patterns in cell-free tumor DNA in serum/plasma. Ongoing work is bringing these methods together for the analysis of samples from large clinical trials, which have been collected well in advance of cancer diagnosis. These efforts pave the way for the development of a noninva

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FK - Gynekologie a porodnictví

OECD FORD obor

—

Projekt

<a href="/cs/project/7E13033" target="_blank" >7E13033: Epigenetics for female personalized cancer care</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Epigenomics

ISSN

1750-1911

e-ISSN

—

Svazek periodika

6

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

17

Strana od-do

311-327

Kód UT WoS článku

000340668300013

EID výsledku v databázi Scopus

—